In pursuit of accessible sickle cell cure, Novartis inks $1.5B deal to tap Precision's ARCUS gene editing tech

Amber Tong

Novartis brought in another biotech partner on its quest to create an in vivo gene editing therapy for sickle cell disease and other similar blood …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In pursuit of accessible sickle cell cure, Novartis inks $1.5B deal to tap Precision's ARCUS gene editing tech

Amber Tong

Sign up to read this article for free.

Danish biotech Gubra touts early weight loss data in hot amylin field

After stock slides, Amgen addresses bone density talk on obesity drug

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

In pur­suit of ac­ces­si­ble sick­le cell cure, No­var­tis inks $1.5B deal to tap Pre­ci­sion's AR­CUS gene edit­ing tech

Amber Tong

Sign up to read this article for free.

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

In pursuit of accessible sickle cell cure, Novartis inks $1.5B deal to tap Precision's ARCUS gene editing tech

Danish biotech Gubra touts early weight loss data in hot amylin field

After stock slides, Amgen addresses bone density talk on obesity drug

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?